Literature DB >> 20498639

CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1.

V Leone1, G Mansueto, G M Pierantoni, M Tornincasa, F Merolla, A Cerrato, M Santoro, M Grieco, A Scaloni, A Celetti, A Fusco.   

Abstract

RET/papillary thyroid carcinoma 1 (PTC1) oncogene is frequently activated in human PTCs. It is characterized by the fusion of the intracellular kinase-encoding domain of RET to the first 101 amino acids of CCDC6. The aim of our work is to characterize the function of the CCDC6 protein to better understand the function of its truncation, that results in the loss of the expression of one allele, in the process of thyroid carcinogenesis. Here, we report that CCDC6 interacts with CREB1 and represses its transcriptional activity by recruiting histone deacetylase 1 and protein phosphatase 1 proteins at the CRE site of the CREB1 target genes. Finally, we show an increased CREB1 phosphorylation and activity in PTCs carrying the RET/PTC1 oncogene. Consistently, an increased expression of two known CREB1 target genes, AREG and cyclin A, was observed in this subgroup of thyroid papillary carcinomas. Therefore, the repression of CREB1 activity by CCDC6 has a critical function in the development of human thyroid papillary carcinomas carrying RET/PTC1 activation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20498639     DOI: 10.1038/onc.2010.179

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  19 in total

Review 1.  Thyroid Cancer: Role of RET and Beyond.

Authors:  Francesca Carlomagno
Journal:  Eur Thyroid J       Date:  2012-03-28

2.  The circ_FAM53B-miR-183-5p-CCDC6 axis modulates the malignant behaviors of papillary thyroid carcinoma cells.

Authors:  Chong Zhang; Huxia Gu; Dingrong Liu; Fuyun Tong; Huijie Wei; Dan Zhou; Jing Fang; Xiaolu Dai; Haibo Tian
Journal:  Mol Cell Biochem       Date:  2022-05-22       Impact factor: 3.396

3.  OLFM4-RET fusion is an oncogenic driver in small intestine adenocarcinoma.

Authors:  Wenli Liu; Hongzhen Li; Wulin Aerbajinai; Istvan Botos; Griffin P Rodgers
Journal:  Oncogene       Date:  2021-10-21       Impact factor: 9.867

Review 4.  Central role of RET in thyroid cancer.

Authors:  Massimo Santoro; Francesca Carlomagno
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

5.  CRISPR/Cas9-mediated Genomic Editing of Cluap1/IFT38 Reveals a New Role in Actin Arrangement.

Authors:  Tina Beyer; Sylvia Bolz; Katrin Junger; Nicola Horn; Muhammad Moniruzzaman; Yasmin Wissinger; Marius Ueffing; Karsten Boldt
Journal:  Mol Cell Proteomics       Date:  2018-04-03       Impact factor: 5.911

Review 6.  HDAC8 substrates: Histones and beyond.

Authors:  Noah A Wolfson; Carol Ann Pitcairn; Carol A Fierke
Journal:  Biopolymers       Date:  2013-02       Impact factor: 2.505

7.  miR-130b-3p Upregulation Contributes to the Development of Thyroid Adenomas Targeting CCDC6 Gene.

Authors:  Vincenza Leone; Concetta Langella; Francesco Esposito; Marco De Martino; Myriam Decaussin-Petrucci; Gennaro Chiappetta; Antonio Bianco; Alfredo Fusco
Journal:  Eur Thyroid J       Date:  2015-11-21

8.  Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity.

Authors:  Chiara Luise; Francesco Merolla; Vincenza Leone; Simona Paladino; Daniela Sarnataro; Alfredo Fusco; Angela Celetti
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

9.  Loss of CCDC6 affects cell cycle through impaired intra-S-phase checkpoint control.

Authors:  Angeliki Thanasopoulou; Dimitrios J Stravopodis; Konstantinos S Dimas; Juerg Schwaller; Ema Anastasiadou
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

10.  Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma.

Authors:  Elisa Menicali; Sonia Moretti; Pasquale Voce; Serena Romagnoli; Nicola Avenia; Efisio Puxeddu
Journal:  Front Endocrinol (Lausanne)       Date:  2012-05-22       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.